City of Hope Medical Center: Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials
The registry lists 10 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies with City of Hope Medical Center as lead sponsor. 1 are open to participants now and 4 have results posted.
Phase 1 4Phase 2 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantRecruitingNCT06059391Phase 2
- High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell TransplantCompletedNCT03128359Phase 2Results posted
- Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT02396134Phase 2Results posted
- Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
- Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid CancerTerminatedNCT00540995Phase 1/2Results posted
- Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological MalignanciesCompletedNCT04681105Phase 1
- Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood CancerWithdrawnNCT03739606Phase 2
- Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell TransplantWithdrawnNCT03438344Phase 2
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00816283Phase 1